Literature DB >> 29273111

Alopecia Areata: The Clinical Situation.

Maria K Hordinsky1.   

Abstract

In the absence of an approved treatment by the US Food and Drug Administration, choosing one of the many off-label treatments available for a child, teen, or adult with alopecia areata (AA) can be challenging. The physician or midlevel provider treating a patient with AA needs to take into consideration the age of the patient, location of hair loss, disease extent and activity, and any ongoing medical or psychological issues. Many patients and their families have now also heard the "buzz" about evolving research, particularly with JAK inhibitors, for the treatment of AA. This means that today's clinic visit with the AA patient should include not only a discussion about traditionally used off-label treatments but also evolving therapies and clinical research opportunities.
Copyright © 2017 The Author. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29273111     DOI: 10.1016/j.jisp.2017.10.015

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  1 in total

1.  Mesalazine in the Treatment of Extensive Alopecia Areata: A New Therapeutic Option?

Authors:  Ana Elisa Kiszewski; Mariele Bevilaqua; Luciana Boff De De Abreu
Journal:  Int J Trichology       Date:  2018 May-Jun
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.